Evidence map›Paper›PMID 35185612›Full record

ArticleFrontiers in physiology2022

Role of Myostatin in Muscle Degeneration by Random Positioning Machine Exposure: An

Ida Cariati, Manuel Scimeca, Roberto Bonanni, Rebecca Triolo, Valerio Naldi, Giuseppe Toro, Mario Marini, Virginia Tancredi, Riccardo Iundusi, Elena Gasbarra and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Sarcopenia and bone health: new acquisitions for a firm liaison.Therapeutic advances in musculoskeletal disease · 2022
    Review
  16. Osteosarcopenia and Long-COVID: a dangerous combination.Therapeutic advances in musculoskeletal disease · 2022
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ida CariatiPh.D. in Medical-Surgical Biotechnologies and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Manuel ScimecaDepartment of Biomedicine and Prevention, "Tor Vergata" University of Rome, Rome, Italy.
Roberto BonanniPh.D. in Medical-Surgical Biotechnologies and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Rebecca TrioloDepartment of Orthopaedics and Traumatology, "Policlinico Tor Vergata" Foundation, Rome, Italy.
Valerio NaldiDepartment of Orthopaedics and Traumatology, "Policlinico Tor Vergata" Foundation, Rome, Italy.
Giuseppe ToroPh.D. in Medical-Surgical Biotechnologies and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Mario MariniDepartment of Systems Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Virginia TancrediDepartment of Systems Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Riccardo IundusiDepartment of Clinical Sciences and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Elena GasbarraDepartment of Clinical Sciences and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
Umberto TarantinoDepartment of Clinical Sciences and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
University of Rome Tor Vergata · ITPoliclinico Tor Vergata · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several scientific evidence have shown that exposure to microgravity has a significant impact on the health of the musculoskeletal system by altering the expression of proteins and molecules involved in bone-muscle crosstalk, which is also observed in the research of microgravity effect simulation. Among these, the expression pattern of myostatin appears to play a key role in both load-free muscle damage and the progression of age-related musculoskeletal disorders, such as osteoporosis and sarcopenia. Based on this evidence, we here investigated the efficacy of treatment with anti-myostatin (anti-MSTN) antibodies on primary cultures of human satellite cells exposed to 72 h of random positioning machine (RPM). Cell cultures were obtained from muscle biopsies taken from a total of 30 patients (controls, osteoarthritic, and osteoporotic) during hip arthroplasty. The Pax7 expression by immunofluorescence was carried out for the characterization of satellite cells. We then performed morphological evaluation by light microscopy and immunocytochemical analysis to assess myostatin expression. Our results showed that prolonged RPM exposure not only caused satellite cell death, but also induced changes in myostatin expression levels with group-dependent variations. Surprisingly, we observed that the use of anti-MSTN antibodies induced a significant increase in cell survival after RPM exposure under all experimental conditions. Noteworthy, we found that the negative effect of RPM exposure was counteracted by treatment with anti-MSTN antibodies, which allowed the formation of numerous myotubes. Our results highlight the role of myostatin as a major effector of the cellular degeneration observed with RPM exposure, suggesting it as a potential therapeutic target to slow the muscle mass loss that occurs in the absence of loading.

Indexed as

muscle degenerationmyostatinrandom positioning machinesarcopeniasatellite cells

Identifiers

PMID35185612
PMCPMC8853288
OpenAlexW4210646889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.